# Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

> **NCT05271552** · PHASE3 · COMPLETED · sponsor: **BioXcel Therapeutics Inc** · enrollment: 151 (actual)

## Conditions studied

- Agitation
- Dementia

## Interventions

- **DRUG:** BXCL501
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT05271552
- **Lead sponsor:** BioXcel Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-27
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-04-21
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05271552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05271552, "Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05271552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*